ENSC vs NKTR

For growth investors, Ensysce Biosciences, Inc.

(ENSC) is the stronger pick with 133. 5% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Analysts rate Nektar Therapeutics (NKTR) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nektar Therapeutics (NKTR) delivered a total return of -72.

3%, compared to -100. 0% for Ensysce Biosciences, Inc. (ENSC). Over 10 years, the gap is even starker: NKTR returned -59. 8% versus ENSC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ensysce Biosciences, Inc.

(ENSC) is the lower-risk stock at 1. 00β versus Nektar Therapeutics's 1. 80β — meaning NKTR is approximately 81% more volatile than ENSC relative to the S&P 500. On balance sheet safety, Ensysce Biosciences, Inc. (ENSC) carries a lower debt/equity ratio of 9% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ensysce Biosciences, Inc.

(ENSC) is pulling ahead at 133. 5% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Ensysce Biosciences, Inc. grew EPS 2. 6% year-over-year, compared to -12. 1% for Nektar Therapeutics. Over a 3-year CAGR, ENSC leads at 13. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ensysce Biosciences, Inc.

(ENSC) is the more profitable company, earning -153. 3% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps -153. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENSC leads at -129. 2% versus -236. 8% for NKTR. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, ENSC (100.

0% yield) pays a dividend. NKTR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ensysce Biosciences, Inc.

(ENSC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), 100. 0% yield). Nektar Therapeutics (NKTR) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ENSC: -100. 0%, NKTR: -59. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ENSC is a small-cap high-growth stock; NKTR is a small-cap quality compounder stock. ENSC pays a dividend while NKTR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.